TALPHERA, INC. Annual Report - How They Did This Year

Hey there! Thinking about TALPHERA, INC. as an investment? Let's break down what they did this past year. This covers their fiscal year ending December 31, 2025. We'll use plain English. This helps you understand the company. We'll cover the important stuff, like how they make money, how much they made (or didn't!), and what might be coming next.

1. What does this company do and how did they perform this year? TALPHERA is a specialty drug company. It develops and sells new medicines for hospitals and medical centers.

   This past year, TALPHERA stopped working on its DSUVIA product. They chose to drop this product. This changes their business focus. DSUVIA's situation is now final. Alora Pharmaceuticals bought DSUVIA from TALPHERA. Alora stopped selling it to most customers in October 2024. They asked the FDA to cancel DSUVIA's approval in 2025. TALPHERA tried to sell it to the military but got no orders. The remaining DSUVIA stock will likely be destroyed. No other company wants to make it. This completely ends their DSUVIA involvement. They won't earn any future money from it.

   They also bought Lowell Therapeutics, Inc. in January 2022 for about $32.5 million. They might pay more later based on future goals. This added new products and technologies to their lineup. Specifically, they gained nafamostat-based drug candidates.

   Their main focus now is Niyad. This is their top drug candidate. Niyad is a drug they are developing. It's a regional anticoagulant. It helps patients in hospitals getting continuous renal replacement therapy (CRRT). This is important because Niyad got an Investigational Device Exemption (IDE) and Breakthrough Device Designation from the FDA. These can speed up its review. Its main clinical trial is happening now. They expect it to finish in 2026. TALPHERA thinks Niyad could be the first and only FDA-approved regional anticoagulant for CRRT. It could reach over $200 million in U.S. yearly sales. This is if it gets approval for CRRT and Intermittent Hemodialysis (IHD). They estimate the CRRT patient market is worth $575 million. The IHD patient market is a huge $3.5 billion. This shows a big market opportunity.

   They also have another drug candidate called LTX-608. It's a different version of Niyad's active ingredient, nafamostat. They are exploring LTX-608 for conditions like disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), acute pancreatitis, or as an anti-viral treatment. They aim for DIC or acute pancreatitis first. Over 250,000 DIC patients live in the U.S. each year. This is another big market.

   Lastly, they have two "PFS Products" (pre-filled syringes) called Fedsyra and Phenylephrine. They are considering stopping these products. Other FDA-approved pre-filled syringes are already available. They want to focus on their nafamostat products (Niyad and LTX-608). This shows they are prioritizing their drug pipeline.

2. Financial performance - revenue, profit, growth metrics TALPHERA tracks common business costs. These include Selling, General, and Administrative expenses (SG&A). SG&A covers daily costs for running the business and selling products. They also track Research and Development (R&D) expenses. R&D pays for creating new products or improving old ones. They mention these for 2024 and 2025. This shows ongoing spending in these areas.

   The company has lost a lot of money since it started. They expect to keep losing money in the future. This means they are not yet making a profit. They are in a development phase. Their costs are higher than their income. They also say they may never make a profit. This is a big risk for investors. To fund their work, especially Niyad's development, they sold rights to future DSUVIA payments (royalties and milestones) to XOMA in January 2024. This shows they needed cash and sold off an asset.

3. Major wins and challenges this year Challenges:

   • Staying in Business is Questionable: This is a very serious concern for investors. The company's auditors doubt they can stay in business. This means the company might not survive long-term. They need big changes or new money. Their current cash might not cover costs for the next year.
   • Nasdaq Listing Risk: Their shares might lose their Nasdaq listing. If delisted, investors will find it harder to trade their stock. This reduces how easily you can sell it. It could also drop the share price a lot.
   • Shareholder Lawsuit: A shareholder lawsuit is a big challenge for TALPHERA. The lawsuit claims they broke securities laws. These laws cover fraud when buying or selling stock. This serious legal issue could hurt their money and reputation. It might lead to big payments or settlements.
   • DSUVIA's Definitive Failure: DSUVIA, once a strategic focus, is now a complete failure. Alora Pharmaceuticals stopped selling it to most customers in October 2024. They asked the FDA to cancel its approval in 2025. Remaining stock will likely be destroyed. This product is completely gone. They won't earn future money from it. This is a big loss.
   • Potential Discontinuation of PFS Products: The company will likely stop developing Fedsyra and Phenylephrine. These products won't bring in future income. This narrows their drug pipeline.
   • Lowell Acquisition Benefits Not Realized: They might not get the expected benefits from buying Lowell Therapeutics. This could hurt their stock price. It could also reduce the return on their $32.5 million investment.
   • Ongoing Losses: The company has always lost money and expects to keep doing so. They have no guarantee of ever making a profit. So, they rely on outside money to keep running.
   • Increasing Pricing Pressure: The company expects more pressure from healthcare payers (like insurers and hospitals). They may need to offer bigger discounts or rebates. This could cut the actual money they make from sales, even for successful products.

   Wins (or positive developments):

   • Capital Raising: TALPHERA actively raised money. They used "private placements" and "prefunded warrants" in January 2024, April 2025, and September 2025. These are key ways companies get money from investors. This is vital for operations and growth, especially with their financial struggles and losses.
   • Funding for Niyad: They sold rights to future DSUVIA payments to XOMA in January 2024. This specifically funded Niyad's development. This shows commitment to their top product. It's a smart move to fund its progress.
   • Acquisition of Lowell Therapeutics: Buying Lowell Therapeutics could be a win. It might bring valuable new products or technologies, especially the nafamostat-based drug pipeline. But there's a risk it won't work out as planned.
   • Niyad's Strong Potential: Niyad received Breakthrough Device Designation from the FDA. This speeds up its development and review. It also got an ICD-10 procedural code from U.S. Medicare & Medicaid. This helps with future payments and market entry. Its main clinical trial is underway, expected to finish in 2026. They believe Niyad could be the first and only FDA-approved regional anticoagulant for CRRT. It has an estimated peak sales potential of over $200 million annually in the U.S. This addresses a big unmet medical need.

4. Financial health - cash, debt, liquidity The biggest news is the "substantial doubt about staying in business." This means the company faces big financial problems. It needs more money to keep operating. They clearly state they "need more money and might not get it." This could force them to shrink or even shut down. This is a critical risk for investors.

   The company has been active financially. They used "private placements" and "warrants" (April 2025, September 2025) to raise money. For example, in January 2024, they made a deal with XOMA. They sold rights to future DSUVIA payments to fund Niyad. This directly affects their cash and ability to pay bills (liquidity). They hold cash, cash equivalents, U.S. government debt, and Money Market Funds. These are generally safe, easy-to-sell investments. They also mention a "Warrant In Connection With Oxford Finance Loan Agreement." This suggests they have debt or financing, possibly backed by warrants.

   To fund operations, they might sell more stock. This could dilute existing shares, meaning your ownership percentage shrinks. Or they might take on more debt. This could restrict their business and increase financial risk. They've also stated they've lost a lot of money since they started and expect to keep losing money. They may never make a profit. This shows they rely on outside money.

5. Key risks that could hurt the stock price

   • Company Survival: This is the most critical risk. Auditors doubt the company can keep operating. If they can't raise enough money, they might shut down. Investors could lose everything.
   • Nasdaq Delisting: If the company fails Nasdaq's listing rules (like minimum price, market value, or shareholder equity), its stock could be removed. This makes it much harder to trade. It could also cause a big drop in value and investor trust.
   • Legal Troubles: The ongoing shareholder lawsuit claims they broke securities laws. This is a big risk. Such cases cost a lot of money and time. They could hurt the company's reputation and stock price. Also, their dealings with doctors and partners must follow strict anti-kickback and fraud laws. Breaking these could mean big penalties. They also face expensive patent lawsuits. These could threaten their intellectual property.
   • Share Dilution from Warrants: The company issued different types of warrants. If exercised, new shares will be issued. This can dilute existing shares, meaning your ownership percentage shrinks. Also, if many existing shares are sold (e.g., by private placement investors), it could push the stock price down. This happens due to increased supply.
   • DSUVIA's Complete Failure: DSUVIA's definitive end, with its approval canceled and stock destroyed, means a past product completely failed to make steady money. This could hurt investor trust. It's a big loss of a past asset.
   • PFS Product Discontinuation: They will likely stop the Fedsyra and Phenylephrine pre-filled syringe products. This means those potential income sources are gone. This further narrows their immediate drug pipeline.
   • Clinical Trial & Regulatory Approval Hurdles for Niyad & LTX-608: This is a huge, expensive, and uncertain journey for any drug company. Niyad and LTX-608 are still in trials or early development. Getting them approved is their main way to future income.
     • The Trial Process is Tough: Drugs typically go through three main phases:
       • Phase 1: Small group, usually healthy people (or very sick patients for serious diseases). They check safety and how the body handles the drug.
       • Phase 2: Limited patients test if it works, find the right dose, and check for side effects.
       • Phase 3: Large patient groups across many locations confirm effectiveness and safety. They gather data for labeling.
     • Lots of Money & Time: Each phase needs a lot of time, effort, and money. There's no guarantee of quick approval, or any approval.
     • Trials Can Stop: The FDA or the company can stop a trial anytime. This happens if there are safety concerns or other issues. An independent review board (IRB) can also stop a trial. This happens if rules aren't followed or patients are at risk.
     • Manufacturing Challenges: Even with good trials, they must consistently make the drug in large quantities. They must meet strict quality standards (cGMP for drugs, QSR for devices). This means much testing to ensure the product stays stable.
     • FDA Scrutiny & No Guarantees: After trials, they submit a huge application (like an NDA or PMA) to the FDA. This costs a lot in fees. The FDA inspects their manufacturers and trial sites. The FDA might disagree with their trial data. Or they might ask for more studies or information. If the FDA isn't satisfied, they issue a "Complete Response Letter." This means the application isn't ready and needs major work. This causes big delays and costs more money. They also must test the drug for kids, adding complexity.
     • Delays & Failures are Common: Any delays increase costs and push back product sales. If trials don't show safe, effective drugs, or if serious side effects appear, they could face more costs, delays, or abandon development. Finding enough patients for trials can also cause delays.
   • Ongoing Regulatory Compliance & Post-Market Burdens: Even with approved products, the company faces many ongoing rules. These include strict manufacturing quality rules (like FDA's QSMR). They also control how products are labeled and promoted (no "off-label" uses). They must report if devices cause serious harm or malfunction. They manage recalls and monitor products after market launch. These rules are complex and costly. Any mistake could mean penalties or product removal.
   • International Regulatory Hurdles: If TALPHERA sells products outside the U.S., they must navigate new foreign rules for trials, sales, and distribution. These can be very different, adding complexity and cost.
   • Specific Product Regulations (e.g., Fedsyra): Products like Fedsyra contain ephedrine. They face strict controls and quotas under laws like the Combat Methamphetamine Epidemic Act. They are considering stopping Fedsyra. But managing such regulated substances adds complexity and risk.
   • Commercialization Challenges:
     • Competition: If they can't compete well, their products might not sell as much as possible.
     • Intense Pricing Pressure and Government Intervention: Even with approved products, TALPHERA struggles to get good prices and insurance coverage. They expect more pressure from healthcare payers (like government, insurers, hospitals). They may need to offer bigger discounts or rebates. This could significantly cut the actual money they get for their drugs (net prices). Also, the government increasingly controls drug prices. For example, U.S. HHS can impose rebates if drug prices rise faster than inflation. More importantly, HHS can now negotiate prices for certain Medicare drugs. This is through the Medicare Drug Price Negotiation Program, which started in 2023. These changes could seriously hurt TALPHERA's profit. Sales could drop if competitors offer cheaper or better alternatives.
     • Reimbursement: Even if approved, their products might not get good insurance coverage or payment in the U.S. or Europe. This makes profitable sales difficult.
     • Group Purchasing Organizations (GPOs): Failing to build ties with these large buying groups (GPOs), which have big buying power for hospitals, could hurt future income.
     • Legislation: New laws could make selling products harder or more expensive. They could also affect prices.
     • Niyad Sales Strategy: They are still deciding whether to use their own sales team or partner with another company to launch Niyad. This decision has risks for market entry and success. Building an internal sales team costs a lot.
   • Lowell Acquisition Underperformance: If buying Lowell Therapeutics doesn't bring expected benefits, it could hurt the company's value and the return on their $32.5 million investment.
   • Operational Risks:
     • Reliance on Third Parties: They rely heavily on outside manufacturers and suppliers (some are single sources). These provide drug ingredients and finished products, mainly from Asia and the U.S. For Niyad, they use single contract manufacturers for both the active ingredient and finished product. They are discussing a back-up. Any problems with these single suppliers could cause big delays in development or sales.
     • Manufacturing Issues: Manufacturing problems could delay development or increase costs.
     • They also rely on outside parties to run and monitor clinical trials. This creates external dependencies.
     • IT Systems & Data Security: Computer system disruptions or data breaches could cause big financial, legal, and reputational harm. This is especially true with sensitive patient data.
     • Business Interruptions: General interruptions (like natural disasters, pandemics) could delay operations and sales.
     • Key Personnel: Their future success depends on keeping key executives and attracting skilled staff. This is tough in a competitive biotech job market.
   • Small Market Capitalization: The company's market value (total value of all shares) was about $8.3 million as of June 30, 2025. This is a very small company (a micro-cap). Its stock can be more volatile, less liquid, and riskier for investors. As of March 18, 2026, 50,049,824 shares existed.
   • Stock Price Volatility: Their stock price has been very volatile, and may stay that way. This is due to trial results, financing, and market feelings for small biotech companies.
   • Anti-Takeover Provisions: Company rules and Delaware law could make it harder or costlier for another company to buy them. This is true even if it benefits shareholders. It could limit exit chances or higher valuations.
   • Macroeconomic Uncertainties: Broader economic issues (like inflation, supply chain problems, labor shortages, recession risks) could hurt their business. This could raise costs or impact healthcare spending.

6. Competitive positioning The CRRT anticoagulant market includes heparin. Heparin affects the whole body. It also includes citrate, a regional anticoagulant. Doctors use citrate "off-label," meaning the FDA hasn't specifically approved it for CRRT.

   Market research shows heparin is used 43% of the time. Citrate is used 28% of the time. In the remaining 29% of cases, no anticoagulant is used. Doctors often avoid anticoagulants. They worry about heparin's safety (it can cause bleeding in 66.7% of cases, versus 4.3% with nafamostat in one study). Or they worry about citrate's complexities. Citrate can cause low calcium, "citrate lock," and calcium shortages. It also needs much nursing time to give and monitor. Also, citrate is unusable for liver failure patients. This affects about 43% of acute kidney injury patients. When no anticoagulant is used, filters often clog. This leads to more blood transfusions and less efficient CRRT.

   TALPHERA believes Niyad, if approved, could be a key option. This is especially true for patients who can't use current products due to safety or other medical reasons. Niyad aims to be the first and only FDA-approved regional anticoagulant for CRRT. Its active ingredient, nafamostat, has been used safely in Japan and South Korea for over 30 years. It's used for similar purposes. This could give it an advantage with known safety. They see their main chance in the 57% of the market now using citrate or no anticoagulant. Niyad could offer a safer, more effective choice.

   For LTX-608, they believe nafamostat could treat other conditions. These include DIC (Disseminated Intravascular Coagulation) or acute pancreatitis. It's already approved for these in Japan and South Korea. This shows it works for these uses.

7. Leadership or strategy changes The biggest strategic change is the definitive end of DSUVIA operations. This shows a complete shift from that product and its income sources. Buying Lowell Therapeutics, Inc. in January 2022 for $32.5 million is another big strategic move. It brought new assets and the nafamostat-based drug pipeline into the company. Their strategy now clearly focuses on developing, approving, and selling Niyad. They also plan to add more acute care therapies to their lineup. Their focus clearly shifted to Niyad as their top drug candidate. This means they are focusing on one high-potential asset. They are also considering stopping two pre-filled syringe drug candidates (Fedsyra and Phenylephrine). This helps them focus resources on their main nafamostat programs. They are strategically deciding LTX-608's first use. This shows careful drug pipeline management.

8. Future outlook TALPHERA's future outlook is heavily influenced by "substantial doubt about staying in business." Their immediate future depends on successfully raising more money. This funds operations and product development.

   They strategically decided to stop DSUVIA and buy Lowell Therapeutics. They also named Niyad their top drug candidate. This shows they re-evaluated their products. They likely aim to focus on more promising areas. Niyad's main clinical trial should finish in 2026. This is a key milestone. It will determine the path for this critical asset. However, as risks show, the path from trial completion to FDA approval and market launch is long and complex. It needs many resources and faces many hurdles. If approved, Niyad could reach over $200 million in U.S. yearly sales. This addresses a large market. They are actively preparing Niyad's sales and marketing. This includes deciding on their own sales team or a partner. This decision is crucial for market entry. They are also evaluating LTX-608's next steps. This includes submitting an Investigational New Drug (IND) application for a Phase 2 study. This shows continued drug pipeline development.

   The company actively plans and secures funding. They use private placements and warrants. This includes the January 2024 deal to sell DSUVIA payment rights for Niyad. There's no guarantee they will raise enough money. They need it to keep operating and finish development. They could get six years of data exclusivity for Niyad (if approved as a device). They could get five years for LTX-608 (if approved as a new chemical entity). This could protect them from generic competition for a long time. They've also said they may never make a profit. This highlights their business's high-risk, high-reward nature.

9. Market trends or regulatory changes affecting them The shareholder lawsuit mentions violations of SEC rules (Sections 10b, 20a, and Rule 10b-5). This highlights the importance of following rules in their industry. Legal challenges could impact operations and investor trust. Any negative findings could mean more regulatory oversight. It could also impact how the company operates.

   Niyad's clinical trial risks also highlight big regulatory hurdles in the drug industry. Getting FDA approval (like an NDA or PMA) is long, expensive, and can have unexpected delays. This involves tough clinical trial phases and strict manufacturing standards (cGMP, QSR). The FDA scrutinizes intensely, including inspections. They might require more data if not satisfied. Positive regulatory steps for Niyad include its Breakthrough Device Designation. This can speed up the review process. It also got an ICD-10 procedural code. This is crucial for future payment and market access. Alora Pharmaceuticals asked the FDA to cancel DSUVIA's approval in 2025. This is a big regulatory action. It marks the definitive end of that product and its regulatory status.

   Other factors include FDA enforcement against "off-label" drug promotion. Existing and future laws also impact their ability to sell products and set prices. They also risk complying with healthcare anti-kickback, fraud, and abuse laws. Violations carry severe penalties.

   • Growing Government Scrutiny and Intervention in Drug Pricing: A major trend is increasing government focus on drug pricing. U.S. HHS can impose rebates on Medicare Part B and D products. This happens if prices rise faster than inflation. Crucially, HHS can now negotiate prices for certain Medicare drugs. This is through the Medicare Drug Price Negotiation Program, which started in 2023. These proposals constantly evolve. They could significantly impact TALPHERA's ability to sell products profitably. This affects their income and business model by limiting prices.